|
Day 2. Saturday, 14 October 2023
8.30am to 6pm
|
|
Moderators: Dr. Kakil Rasul & Dr. Mai Mostafa
|
|
8am to 8.30am
|
Registration
|
|
|
8.30am to 8.50am
|
Gastrointestinal Cancer - Colorectal/Anal (Abstract 3508): Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial
|
Dr. Kakil Rasul,
Senior Consultant Medical Oncologist, NCCCR
|
|
8.50am to 9.10am
|
Gastrointestinal Cancer - Colorectal/Anal (Abstract LBA2): PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048)
|
Dr. Mai Mostafa
Consultant Medical Oncologist, NCCCR
|
|
9.10am to 9.30am
|
Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract 4000): ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer
|
Dr. Aleem Akram
Associate Consultant Medical Oncologist, NCCCR
|
|
9.30am to 9.50am
|
Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract 4014& 4027): Treating Gastroesophageal Cancer: New Lights on the Horizon
|
Dr. Alaaeldin Shablak
Consultant Medical Oncologist, NCCCR
|
|
9.50am to 10.05am
|
PANEL DISCUSSION
|
|
10.05am to 10.25am
|
Coffee Break
|
|
Moderators: Dr. Alaaeldin Shablak & Dr. Azza Adel Hassan
|
|
10.25am to 10.45am
|
Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract 4006): Liposomal irinotecan + 5-fluorouracil/ leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial
|
Dr. Mohamed Siralkhatim Hamid
Consultant Medical Oncologist, NCCCR
|
|
10.45am to 11.05am
|
Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract 4008): Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC)
|
Dr. Arwa Isameldin
Consultant Medical Oncologist, NCCCR
|
|
11.05am to 11.25am
|
Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract LBA4005): Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1)
|
Dr. Wamda Abdalla
Medical Oncologist, NCCCR
|
|
11.25am to 11.45pm
|
Symptom and Survivorship (Abstract 12005): Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine
|
Dr. Ayman Allam
Senior Consultant, Supportive & Palliative Care, NCCCR
|
|
11.45pm to 12pm
|
PANEL DISCUSSION
|
|
12pm to 1pm
|
Prayer & Lunch Break
|
|
Moderators: Dr. Anas Hamad & Dr. Reyad Mohsen
|
|
1pm to 1.20pm
|
Health Services Research and Quality Improvement: No Time to Lose: Early Access to Precision Oncology
|
Dr. Anas Hamad
Director of Pharmacy Department, NCCCR
|
|
1.20pm to 1.40pm
|
Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology (Abstract LBA3000): Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results
|
Dr. Shereen Elazzazy
Assistant Director of Pharmacy for Clinical Services, NCCCR
|
|
1.40pm to 2pm
|
Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology (Abstract 3006): Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study
|
Dr. Hebatalla Afifi
Clinical Pharmacist, NCCCR
|
|
2pm to 2.20pm
|
Lung Cancer—Non-Small Cell Metastatic (Abstract LBA9000): Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study
|
Dr. Ussama Al Homsi
Deputy Medical Director for Education, Research and Quality, Senior Consultant Medical Oncologist, NCCCR
|
|
2.20pm to 2.40pm
|
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (Abstract LBA100): KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
|
Dr. Reyad Mohsen
Senior Consultant Medical Oncologist, NCCCR
|
|
2.40pm to 3pm
|
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (Abstract LBA3): OS survival analysis from the ADURA trial of adjuvant osimertinib in patients with resected EGFR-mut stage 1B-IIIA NSCLC
|
Dr. Ammar Madani
Associate Consultant Medical Oncologist, NCCCR
|
|
3pm to 3.20pm
|
PANEL DISCUSSION
|
|
3.20pm to 3.40pm
|
Prayer & Coffee Break
|
|
Moderators: Dr. Abdul Rehman Zar & Dr. Al Hareth Al Khater
|
|
3.40pm to 4pm
|
Head and Neck Cancer (Abstract 6007): Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial
|
Dr. Abdulrehman Zar Gul
Senior Consultant Medical Oncologist, NCCCR
|
|
4pm to 4.20pm
|
Head and Neck Cancer (Abstract 6005): Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
|
Dr. Aladdin Kanbour
Consultant Medical Oncologist, NCCCR
|
|
4.20pm to 4.40pm
|
Head and Neck Cancer (Abstract LBA6002): PD-1 blockade with Sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): a multicenter, phase 3, randomized controlled trial (CONTINUUM)
|
Dr. Hissa Al-Abdulla
Senior Consultant Radiation Oncologist, NCCCR
|
|
4.40pm to 5pm
|
Genitourinary - Kidney/Bladder (Abstract LBA4501): Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426
|
Dr. Al Hareth Al Khater
Deputy Medical Director for Clinical Affairs, Senior Consultant Medical Oncologist, NCCCR
|
|
5pm to 5.20pm
|
Genitourinary - Kidney/Bladder (Abstract LBA4500): Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study
|
Dr. Hassan Aakel
Medical Oncologist, NCCCR
|
|
5.20pm to 5.40pm
|
Genitourinary - Prostate, Testicular and Penile (Abstract LBA5000): Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design
|
Dr. Mohamed Riyas
Senior Consultant Radiation Oncologist, NCCCR
|
|
5.40pm to 6pm
|
PANEL DISCUSSION
|
|
6pm
|
Closing Ceremony
|
Dr. Mohammed Ussama Al Homsi
Deputy Medical Director for Education, Research and Quality, Senior Consultant Medical Oncologist, NCCCR
|
